Abstract: Glycine betaine based liquid crystal comprising in dry matter at least: 80 to 99.5% by weight of glycine betaine, and 0.5 to 20% by weight of a non-ionic water soluble tensioactive system having a HLB value equal to 12 or more than 12, whereby the weight ratio glycine betaine/non-ionic water soluble tensioactive system is greater than 10, said glycine betaine and said non-ionic water soluble tensioactive being solubilized in water for forming the glycine betaine based liquid crystal.

Abstract: The invention describes the use of betaine alone for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.

Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Abstract: The invention describes the use of betaine for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.

Abstract: The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both immunological and functional (activity) expression of Tissue Factor Pathway Inhibitor (TFPI) in a mammal, particularly a human.

Abstract: The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH3)3N+(CH2)nCOO? with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that the second compound is different from the first compound and in an amount by weight at least three times the amount of first compound.

Abstract: The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both immunological and functional (activity) expression of Tissue Factor Pathway Inhibitor (TFPI) in a mammal, particularly a human.

Abstract: Use of glycine betaine as therapeutically active ingredient for the preparation of a medicament and/or a nutritional product and/or a dietary supplement for treating human resistant to a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, who suffers from a disease requiring the administration of a compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof, or who is at risk of suffering of said disease, whereby the medicament comprises an effective amount of glycine betaine for decreasing by at least 10%, advantageously at least 20% the resistance of said patient to said compound selected from the group consisting of aspirin, clopidogrel, thienopyridines and combinations thereof

Abstract: An oral control release formulation for releasing at least one betaine after oral administration to a human, said formulation comprising at least one pharmaceutically acceptable means ensuring an at least partial floating of the formulation releasing at least one betaine in the gastro-intestinal tractus.

Abstract: A pharmaceutical association or combination comprising a therapeutic effective amount of insulin or insulin analogue, and a therapeutic effective amount of a pharmaceutically acceptable betaine, in which the insulin and the betaine possibly form a chemical entity or complex, and in which the amount of betaine is adapted for controlling the degradation and/or for increasing the duration of action and/or for enhancing the therapeutically effect of the insulin or insulin analogue.

Abstract: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound selected from one or more of betaines, lipidic betaines, betaine lipids and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, .alpha.-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound selected from one or more of betaines, lipidic betaines, betaine lipids is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound selected from one or more of betaines, lipidic betaines, betaine lipids.

Abstract: The invention describes the use of betaine for treating and preventing arterites. The invention also describes an orally administered composition for treating arterites and, in particular, intermittent claudication, said composition containing, as an active ingredient, an active therapeutic quantity of betaine glycine by single dose. The invention particularly describes a medicament provided for treating a patient suffering from an intermittent claudication caused by peripheral circulatory disorders such as arteriosclerosis obliterans or by thromboangiitis obliterans.

Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Abstract: A physiologically acceptable, sterile and pyrogen-free solution of betaine dissolved in a physiologically acceptable solvent, having a pH adjusted to from 5.0 to 8.0 with a betaine concentration of from 5 to 500 mg/ml.

Abstract: The present invention provides pharmaceutical uses of betaines, and especially glycine betaine, such as for the treatment of thromboses not induced by hyperhomocystenemia or homocystinuria, of blood disorders, such as blood coagulation and thrombi formation.

Abstract: A pharmaceutical association or combination comprising a therapeutic effective amount of insulin or insulin analogue, and a therapeutic effective amount of a pharmaceutically acceptable betaine, in which the insulin and the betaine possibly form a chemical entity or complex, and in which the amount of betaine is adapted for controlling the degradation and/or for increasing the duration of action and/or for enhancing the therapeutically effect of the insulin or insulin analogue.

Abstract: The present invention provides pharmaceutical compositions and methods for the treatment of diabetes mellitus using combination therapy. The compositions relate to a compound of Formula I selected from one or more of betaines, lipidic betaines, betaine lipids and an antidiabetic agent such as sulfonylureas, biguanides, glitazones, .alpha.-glucosidase inhibitors, potassium channel antagonists, aldose reductase inhibitors, glucagon antagonists, activators of RXR, insulin therapy or other anti-obesity agent. The methods include the administration of the combination of compound of Formula I with antidiabetic agent where the two components are delivered in a simultaneous manner, where the compound of Formula I is administered first, followed by the antidiabetic agent, as well as wherein the antidiabetic agent is delivered first followed by the compound of Formula I.

Abstract: The present invention relates to therapeutic compositions of betaines and L-arginine and physiologically acceptable salts thereof, and to pharmaceutical uses of betaines for up-regulating, enhancing, stimulating, controlling and/or increasing constitutive nitric oxide synthase expression a mammal, particularly in a human. Additionally, the betaines are believed to augment after administration both immunological and functional (activity) expression of Tissue Factor Pathway Inhibitor (TFPI) in a mammal, particularly a human.

Abstract: The goal of the present invention is a pharmaceutical composition including a betaine and an anti-cholesterol agent. The association and co-administration of at least a betaine allows to reducing side effects related to anti-cholesterol agents administration, in particular their deleterious effects on liver, pancreas and kidneys.

Abstract: The invention refers to the pharmaceutical combination including at least: a first compound selected among the group consisting of acetylsalicylic acid, salicylic acid, pharmaceutical derivatives thereof, and a second compound selected from the group consisting of lipidic betaines, betaines lipids, betaines of Formula (CH3)3N+(CH2)nCOO? with n an integer from 1 to 5, pharmaceutically acceptable salts thereof, esters thereof, precursors thereof, and mixtures thereof, with the proviso that the second compound is different from the first compound and in an amount by weight at least three times the amount of first compound.